Spots Global Cancer Trial Database for A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Official Title: A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
Study ID: NCT02057133
Conditions
Study Description
Brief Summary: This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
University of California - San Diego, La Jolla, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
Columbia University College of Phys & Surgeons, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Ohio, United States
Providence Cancer Center Oncology Hematology Care, Portland, Oregon, United States
Univ of Pittsburgh Cancer Inst. (UPCI), Pittsburgh, Pennsylvania, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
